Recombinant Human CLEC10A/CD301 protein (rFc Tag)

Species

Human

Purity

>90 %, SDS-PAGE

Tag

rFc Tag

Activity

not tested

Cat no : Eg1892

---

Validation Data Gallery

• 

  Purity of Recombinant Human CLEC10A was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) conditions and stained using Coomassie blue.

---

Product Information

• Purity: >90 %, SDS-PAGE
• Endotoxin: <0.1 EU/μg protein, LAL method
• Activity:

  Not tested

• Expression: HEK293-derived Human CLEC10A protein Gln61-His316 (Accession# Q8IUN9-1) with a rabbit IgG Fc tag at the N-terminus.
• GeneID: 10462
• Accession: Q8IUN9-1
• PredictedSize: 56.0 kDa
• SDS-PAGE: 55-70 kDa, reducing (R) conditions
• Formulation: Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
• Reconstitution: Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
• Storage Conditions:
  It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
• Shipping: The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

C-type lectin domain family 10 member A (CLEC10A), also known as CD301, macrophage galactose-type C-type lectin (MGL), DC-asialoglyco protein receptor (DC-ASGP-R) or human macrophage lectin (HML), is a type II transmembrane glycoprotein having a calcium-dependent carbohydrate recognition domain. CLEC10A is expressed exclusively by myeloid professional antigen-presenting cells such as immature dendritic cells (DCs) and alternatively activated macrophages. CLEC10A is a marker for human CD1c+ DCs (cDC2). It functions as an endocytic receptor for glycosylated antigens.

References:

1. Suzuki N. et al. (1996). J Immunol. 156(1):128-135.
2. Higashi N. et al. (2002). J Biol Chem. 277(23):20686-20693.
3. Valladeau J. et al. (2001). J Immunol. 167(10):5767-5774.
4. van Vliet SJ. et al. (2006). Nat Immunol. 7(11):1200-1208.
5. Heger L. et al. (2018). Front Immunol. 9:744.